Transcript levels of ten-eleven translocation type 1–3 in cervical cancer and non-cancerous cervical tissues

Abstract

Abstract. Decreased expression of ten-eleven translocation (TET1, TET2 and TET3) proteins has been reported in various types of cancer. However, the expression levels of TET proteins in cervical cancer (CC) remain to be elucidated. The present study determined the levels of TET1, TET2 and TET3 transcripts in cancerous (n=80) and non-cancerous cervical tissues (n=41). The results revealed a significant reduction in TET1 transcripts (P=0.0000001) in cervical tissue samples from patients with primary CC compared with samples from control patients. Significantly decreased TET1 transcript levels, as compared to non-cancerous cervical tissues, were also observed in tissue samples with the following characteristics: Stage I (P=0.016), II (P<0.0001), III (P=0.00007) and grade of differentiation G1 (P=0.026), G2 (P=0.00006), G3 (P=0.0007) and Gx (P=0.0004) and squamous histological type (P<0.00001). TET1 transcript levels were significantly lower in patients aged 45-60 years (P=0.0002) and patients age >60 years (P=0.003), as compared with non-cancerous cervical tissues. TET2 transcript levels were lower in cervical cancer tissues classified as stage II (P=0.043) and TET3 transcript levels were lower in stage III samples (P=0.010), tissue samples with a grade of differentiation of G3 (P=0.025) and tissue with squamous type histology (P=0.047), all compared with non-cancerous cervical tissues. The present study demonstrated a significantly reduced level of TET1 transcripts in cancerous cervical tissues, as compared with non-cancerous tissues. Furthermore, decreased TET1-3 transcript levels were identified when patients with CC were stratified by clinicopathological variables, as compared with non-cancerous cervical tissues.

Expression and prognosis analysis of TET family in acute myeloid leukemia

“…Several studies revealed that high expression of TET3 was revealed in renal cell carcinoma as well as endometrial cancers, and high mRNA levels of TET3 were independent predictors of poor outcome in renal cell carcinoma patients [29,30]; whereas, several other investigations reported that TET3 was low-expressed in diverse human cancers. For instance, Bronowicka-Kłys et al showed that TET3 transcript levels were lower in stage III samples of cervical cancer [31]. Moreover, TET3 mRNA was decreased in chronic lymphocytic leukemia cells compared with healthy B cells [32].…”

Epigenetic Regulation of p21cip1/waf1 in Human Cancer

“…Histone deacetylation is removed by zinc-dependent Class I, II, and IV histone deacetylases (HDAC) or Nicotinamide adenine dinucleotide + (NAD+)-dependent sirtuins that are also referred to as Class III HDACs. HDACs remove ε-amino acetyl groups from lysine residues in histones and in non-histone proteins (especially mediated by Class II HDACs, which are also found in the cytoplasm), which explains the pleiotropic effects and rather narrow therapeutic window of HDAC inhibitors (HDACi) in humans [42,43]. HDACs are part of larger multi-enzyme complexes, including Sin3, NuRD, and Co-REST, that determine their target recognition and substrate specificity, but also have demethylase properties [44,45].…”

Differential Expression of Steroid Hormone Receptors and Ten Eleven Translocation Proteins in Endometrial Cancer Cells

“…TET2 has been previously implicated in various types of malignancies ( 11 , 42 – 46 ). Data from the present study imply that TET2 protein expression is upregulated when exposed to a combined estrogen-progesterone treatment for 24 hours ( Figure 2 ).…”